1. The effects of intravenous chlorthiazide and frusemide on urinary osmolality were compared in 19 hyponatraemic oedamatous patients.
Introduction
Hyponatraemia associated with an impaired capacity to excrete a water load may occur in patients with sodium-retaining disorders including congestive heart failure, cirrhosis and nephrotic syndrome. The hyponatraemia may be of a degreee to cause or worsen central nervous system symptoms. The infusion of isotonic mannitol solution has been shown to increase the excretion of solute-free water in some patients with cardiac failure [ 11 and cirrhosis 121; such an approach, however, would be contraindicated in the patient with cardiac failure because of the associated expansion of intravascular volume. Demeclocycline increases solute-free water excretion in patients with the syndrome of inappropriate antidiuretic hormone secretion but it causes renal toxicity in patients with hepatic disease 13-51 and azotaemia in patients with congestive heart failure [61.
Diuretics which inhibit sodium chloride reabsorption in the diluting segment of the nephron diminish free water clearance, in normal subjects, and thus could worsen hyponatraemia in some oedematous patients. In a previous study, the loop diuretic, frusemide, increased solute-free water excretion in patients with hyponatraemic oedematous disorders and caused a resistance to vasopressin 171. That study did not, however, demonstrate whether the effects were unique to frusemide or could be observed with any diuretic which increased solute excretion rate to the same degree as frusemide. The present study was undertaken to compare at similar solute excretion rates the effects of frusemide and thiazide diuretics on urine osmolality and the response to 
Methods
The 19 patients selected for this study had clinically stable heart disease, liver disease or nephrotic syndrome and peripheral oedema; they excreted a concentrated urine (urine/plasma osmolality ratio, Uosm~/Posm., greater than 1 .O), had a creatinine clearance greater than 50 ml/min and a serum sodium less than 135 mmol/l. Three patients had congestive heart failure, 15 patients had cirrhosis and one patient had nephrotic syndrome. The study was approved by the Human Research Committee of the University of Colarado Health Sciences Center, Denver, Colorado, U.S.A., and patients gave their signed informed consent to participate in the study.
The patients were divided into four groups, and they were given frusemide (Lasix, HoechstRoussel Pharmaceuticals Inc., Sommerville, NJ, U.S.A.), 1 mg/kg (group 2) or 0.25-0.5 mg/kg (group 3), or chlorthiazide (Diuril, Merck Sharp and Dohme, West Point, PA, U.S.A.), 10 mg/kg (group 1) or 20 mg/kg (group 4). Some characteristics of the patients in each of the four groups are shown in Table 1 ; there were no significant differences between the groups. There was also no difference in non-diuretic drugs used between the four groups.
The studies lasted 4-6 h, during which the patients remained supine except while voiding urine. No food or fluid was permitted for 8 h before or during the study. In eight of 19 patients, at 08.00 hours an infusion of inulin and p-aminohippurate in sufficient concentration to allow clearance measurements was started at 2 ml/min and continued throughout the study. During the first and third hours of the study, these patients also underwent a cardiac output measurement, by injection of indocyanine green dye. In the remaining 11 patients an infusion of glucose solution (50 g/dl) was begun at 08.00 hours on the day of study but no renal clearances or cardiac output measurements were obtained. One hour was allowed for equilibration, after which the patients emptied their bladders and three 20 min control urine collections were made by spontaneous voiding. Blood samples were collected through an indwelling venous catheter at the midpoint of each clearance period. After the three control periods, frusemide or chlorthiazide was injected intravenously and then infused at a constant rate in a dose equivalent to the initial bolus dose per hour. Eight periods of 20 min urine collections were made, starting 20 min after the injection of this diuretic. During the last four of these periods, all patients received 100 m-units of vasopressin/h (Pitressin, Parke-Davis, Morris Plains, NJ, U.S.A.) intravenously. Blood pressure and pulse were measured every 30 rnin during the studies. Urine and plasma samples were anlysed for p-aminohippurate, sodium, potassium, packed cell volume and osmolality. The group results were compared by Student's unpaired t-test [81 and Duncan's new multiplerange test 191.
Results
All patients developed a significant natriuresis after the parenteral diuretic therapy.
Chlorthiazide (10 mg/kg) had no effect on the mean Uos,~/Posl~ (1.54 vs 1.34), but frusemide (1 mg/kg) caused a fall in the mean ratio (1.64 to 0.84, P < 0.01) and the urine became hypotonic (ratio less than 1.0) in every patient. The osmolar clearances (Cosm.) were significantly higher after frusemide than after chlorthiazide (1 1.45 vs 4.99 ml/min, P < 0-01) but there were no significant changes in cardiac output or clearance of p-aminohippurate.
In further studies five patients received intra- chlorthiazide, 20 mglkg (group 4). As shown in Fig. 1 , the osmolar clearances were not significantly different in these two groups. Nevertheless, in the patients receiving low-dose frusemide (group 3), the Uosm.lPosm~ diminished to a mean ratio which was significantly below that of those receiving chlorthiazide (group 4, 1.26 vs 1-00, P < OvOl), even though they started at a higher control ratio (Fig. 2) . In fact, in two of the five patients the urine became hypotonic. (P < 0-Ol), whereas it had no effect in the group 2 patients given the high dose of frusemide (Uosm./Posm. 0-84-0.93). Fig. 2 shows that this difference between the diuretics was also present in the two groups of patients with comparable solute excretion rates. Vasopressin increased Uosm./Posm.in the patients receiving the high dose of chlorthiazide (group 4) from 1.26 to 1.75 (P < 0401), whereas it had no effect on the ratio in the group 4 patients given the low dose of frusemide (1.W1.03).
Discussion
The present results confirm the previous finding that parenteral frusemide, although an inhibitor of sodium chloride transport in the distal diluting segment of the nephron, increases solute-free water excretion in hyponatraemic patients with oedematous disorders [71. The initial dose of the loop diuretic used to induce such an increase in free-water excretion was 1 mglkg. In contrast, intravenous chlorthiazide (10 mglkg) had no effect on the excretion of solute-free water. The increased excretion of solute-free water after frusemide may have been a consequence of its greater potency as a diuretic, as the mean solute excretion rate was much higher after frusemide than after chlorthiazide. An increase in solute excretion has been shown to decrease urinary osmolality in the presence of maximal exogenous doses of vasopressin [lo] . The exact mechanism for this effect is not clear, but it may be due either to a decrease in medullary tonicity, owing to a rise in medullary blood flow. or to an increased rate of tubular fluid flow through the collecting duct with a failure of osmotic equilibration of water. Nevertheless, in normal human subjects 1101, in contrast with monkey [ l l l and dog [121, an increase in solute excretion rate alone rarely makes the urine hypotonic. On the basis of previous results in normal subjects [ 101 the solute excretion rates induced by frusemide (1 mg/kg) would be expected to lower the Uosm~lPosm~ to only 1.3 and not the 0.84 which was observed. The concentrating mechanism in oedematous patients may, of course, respond differently to enhanced solute excretion, but these results suggested that frusemide might reduce urinary osmolality through mechanisms other than the increase in solute excretion.
To test this possibility studies were designed in which diuretic-induced solute excretion was comparable after frusemide and chlorthiazide. The frusemide dose was decreased to 0 . 2 5 4 5 0 mglkg and the chlorthiazide dose was increased to 10 mg/kg; these doses produced comparable excreted a hypotonic urine. Nevertheless, frusemide lowered the ratio more than chlorthiazide did, even at comparable solute excretion rates (Fig. 2) . Moreover, exogenous vasopressin increased the ratio during chlorthiazide administration but not during frusemide administration, and the differences persisted even when the doses of the two diuretics were adjusted to ensure comparable solute excretion rates.
A resistance to vasopressin has been demonstrated in uitro with another loop diuretic, ethacrynic acid, in both isolated perfused cortical collecting tubules [121 and the toad bladder [131. Frusemide, however, had no effect in the toad bladder [131 or isolated collecting tubules [141.
Frusemide increases urinary prostaglandin excretion 115, 161, which could contribute to the resistance to vasopressin. However, because the inhibitors of prostaglandin synthesis cause sodium retention 171 and renal impairment [ 181 in oedematous patients, this possible contribution of prostaglandins to the resistance to vasopressin is probably best tested initially in uitro. The greater effect of frusemide compared with chlorthiazide on solute free water excretion in hyponatraemic oedamatous patients could be related to the different site of action of these diuretics in the nephron. Frusemide inhibits sodium and chloride transport in the medullary ascending limb and also may increase medullary blood flow, so that, like mannitol, it decreases the corticopapillary osmotic gradient. Chlorthiazide diuretics do not diminish the corticopapillary osmotic gradient [ 191. However, mannitol, even at much higher solute excretion rates than those produced by frusemide in the present study, rarely causes production of hypotonic urine in human subjects [lo), perhaps because the corticopapillary osmotic gradient does not become hypo-osmolar. The resistance of vasopressin aRer frusemide is, therefore, more likely to be the result of some direct inhibitory effect on the action of vasopressin to increase water permeability of the collecting duct epithelium.
